COVID-19 has recently created a public health emergency and has been declared a pandemic by the World Health Organization. There are serious concerns regarding surge capacity of UK facilities to cope with a pandemic illness and it is conceivable that the psychological, emotional and physical demands placed on an already overstretched workforce may be substantial.
The CERA study aims to understand the evolving and cumulative effects of working during the COVID-19 outbreak on the psychological health of those physicians working in the emergency care settings across the UK. Physicians will be asked to complete questionnaires on their phones at 3 different time scales; during the Acceleration phase (beginning), during the Peak phase (middle) and during the Deceleration phase (end). It is anticipated that this study will enhance future pandemic preparedness, by highlighting staff resilience and tolerance, and where further support – delivered either during or after an incident – may be beneficial.
The study itself is a TERN project with the support of EMERGE.
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.